Betta Pharmaceuticals Co Ltd (300558) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Betta Pharmaceuticals Co Ltd (300558) has a cash flow conversion efficiency ratio of 0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥224.45 Million ≈ $32.84 Million USD) by net assets (CN¥5.92 Billion ≈ $866.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Betta Pharmaceuticals Co Ltd (300558) total market value for the company's overall valuation and market capitalisation.
Betta Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Betta Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Betta Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Betta Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency. Explore 300558 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asker Healthcare
ST:ASKER
|
0.013x |
|
Manappuram Finance Limited
NSE:MANAPPURAM
|
-0.196x |
|
ShenZhen Special Economic Zone Real Estate & Properties Group Co Ltd
SHE:000029
|
-0.001x |
|
Becle S.A.B. de C.V
MX:CUERVO
|
0.026x |
|
Sinoma International Engineering Co Ltd
SHG:600970
|
0.096x |
|
Sichuan Hebang Biotechnology Co Ltd
SHG:603077
|
0.009x |
|
Shenyang Jinshan Energy Co Ltd
SHG:600396
|
0.098x |
|
Guangzhou Baiyun International Airport Co Ltd
SHG:600004
|
0.048x |
Annual Cash Flow Conversion Efficiency for Betta Pharmaceuticals Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Betta Pharmaceuticals Co Ltd from 2011 to 2025. View today's stock price for Betta Pharmaceuticals Co Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥6.67 Billion ≈ $975.69 Million |
CN¥911.26 Million ≈ $133.35 Million |
0.137x | -15.01% |
| 2024-12-31 | CN¥5.67 Billion ≈ $829.13 Million |
CN¥911.17 Million ≈ $133.33 Million |
0.161x | -5.87% |
| 2023-12-31 | CN¥5.35 Billion ≈ $783.09 Million |
CN¥914.23 Million ≈ $133.78 Million |
0.171x | +176.12% |
| 2022-12-31 | CN¥4.96 Billion ≈ $725.47 Million |
CN¥306.74 Million ≈ $44.89 Million |
0.062x | -44.95% |
| 2021-12-31 | CN¥4.69 Billion ≈ $685.68 Million |
CN¥526.63 Million ≈ $77.06 Million |
0.112x | -27.90% |
| 2020-12-31 | CN¥4.14 Billion ≈ $606.47 Million |
CN¥646.02 Million ≈ $94.53 Million |
0.156x | -30.66% |
| 2019-12-31 | CN¥2.47 Billion ≈ $361.32 Million |
CN¥555.07 Million ≈ $81.22 Million |
0.225x | +76.15% |
| 2018-12-31 | CN¥2.24 Billion ≈ $328.39 Million |
CN¥286.40 Million ≈ $41.91 Million |
0.128x | -5.22% |
| 2017-12-31 | CN¥2.07 Billion ≈ $302.40 Million |
CN¥278.26 Million ≈ $40.72 Million |
0.135x | -36.19% |
| 2016-12-31 | CN¥1.93 Billion ≈ $282.28 Million |
CN¥407.05 Million ≈ $59.56 Million |
0.211x | -51.08% |
| 2015-12-31 | CN¥893.95 Million ≈ $130.81 Million |
CN¥385.56 Million ≈ $56.42 Million |
0.431x | -15.62% |
| 2014-12-31 | CN¥543.03 Million ≈ $79.46 Million |
CN¥277.55 Million ≈ $40.61 Million |
0.511x | -14.31% |
| 2013-12-31 | CN¥319.10 Million ≈ $46.69 Million |
CN¥190.34 Million ≈ $27.85 Million |
0.596x | -31.05% |
| 2012-12-31 | CN¥172.56 Million ≈ $25.25 Million |
CN¥149.29 Million ≈ $21.85 Million |
0.865x | +29.97% |
| 2011-12-31 | CN¥52.28 Million ≈ $7.65 Million |
CN¥34.80 Million ≈ $5.09 Million |
0.666x | -- |
About Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma… Read more